COYA · Coya Therapeutics, Inc.
$4.44
-0.10 (-2.20%)
At close · Jul 20
Market Cap
$106.73M
Shares
23.46M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Arun Swaminathan | CEO | $2,091,007 |
| Howard Berman | CEO | $1,471,701 |
| Fred Grossman | President, Chief Medical Officer | $1,457,433 |
| David Snyder | CFO | $1,368,700 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Howard Berman | CEO | $2,680,268 |
| Fred Grossman | President, Chief Medical Officer | $1,892,438 |
| Arun Swaminathan | CEO | $1,497,168 |
| David Snyder | CFO | $1,465,084 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Howard Berman | CEO | $1,317,200 |
| David Snyder | CFO | $947,888 |
| Adrian Hepner | President, Chief Medical Officer | $622,158 |
| Fred Grossman | President, Chief Medical Officer | $592,482 |
| Arun Swaminathan | CEO | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Adrian Hepner | President, Chief Medical Officer | $726,453 |
| David Snyder | CFO | $608,521 |
| Howard Berman | CEO | $598,125 |
| Fred Grossman | President, Chief Medical Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Howard Berman | CEO | $390,000 |
| Adrian Hepner | President, Chief Medical Officer | $126,851 |
| David Snyder | CFO | — |